Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer

This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes...

Full description

Saved in:
Bibliographic Details
Published in:Future medicinal chemistry 2018-09, Vol.10 (17), p.2039-2057
Main Authors: Tan, Yi Jer, Lee, Yeuan Ting, Yeong, Keng Yoon, Petersen, Sven H, Kono, Koji, Tan, Soo Choon, Oon, Chern Ein
Format: Article
Language:English
Subjects:
BZD9L1
colorectal cancer
sirtuin
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to investigate the mode of action of a novel sirtuin inhibitor (BZD9L1) and its associated molecular pathways in colorectal cancer (CRC) cells. BZD9L1 was tested against metastatic CRC cell lines to evaluate cytotoxicity, cell cycle and apoptosis, senescence, apoptosis related genes and protein expressions, as well as effect against major cancer signaling pathways. BZD9L1 reduced the viability, cell migration and colony forming ability of both HCT 116 and HT-29 metastatic CRC cell lines through apoptosis. BZD9L1 regulated major cancer pathways differently in CRC with different mutation profiles. BZD9L1 exhibited anticancer activities as a cytotoxic drug in CRC and as a promising therapeutic strategy in CRC treatment.
ISSN:1756-8919
1756-8927
DOI:10.4155/fmc-2018-0052